Sentara Healthcare merges with Cone Health to transform Healthcare

Business Wire | August 13, 2020

Sentara Healthcare, headquartered in Norfolk, Va., and Cone Health, headquartered in Greensboro, N.C., have signed a letter of intent to combine organizations. Sentara Healthcare and Cone Health are both regional, community-based health systems with similar missions, cultures, strategies and visions for transforming the future of healthcare. Their joint commitment is simple: to bring together two strong industry leaders into a unified, transformative and value-driven organization at the forefront of change that will be a model for the rest of the nation’s healthcare systems. Sentara Healthcare is an integrated, not-for-profit system comprised of 12 hospitals in Virginia and Northeastern North Carolina. We employ more than 1,200 physicians and advanced practice clinicians, 30,000 team members and operate hundreds of sites of care. Our Optima Health Plan and Virginia Premier Health Plan serve 858,000 members in Virginia, North Carolina and Ohio.

Spotlight

This white paper will outline ways a cloud-based patient relationship management solution can be used to increase revenue for healthcare providers, reduce administrative costs, and give physicians and staff more time focusing on patient care.


Other News
HEALTH TECHNOLOGY

Ivenix to be Acquired by Fresenius Kabi

Ivenix | April 01, 2022

Ivenix, Inc. announced that it has entered into a definitive agreement to be acquired by Fresenius Kabi, a global health care leader specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Ivenix’s advanced infusion system combined with Fresenius Kabi’s intravenous fluids and infusion therapy offerings will bring a comprehensive portfolio of infusion products to U.S. hospitals. The purchase price will be a combination of US$240 million upfront payment and milestone payments linked to achievements of commercial and operating targets. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close by mid-2022. The transaction is designed to Create a comprehensive portfolio that joins the industry’s most advanced infusion pump technology with the newest source of intravenous fluids, infusion supplies and accessories. Accelerate operational and commercial growth and scale providing a platform for rapid expansion. Build on a shared culture of exceptional customer service. Establish Fresenius Kabi as a leader in the approximately $5 billion infusion segment. This pivotal transaction will accelerate innovation, expand our combined infusion therapy portfolio and enhance our infusion capabilities, resulting in improved medication safety and operational efficiency. “We’re very pleased to partner with Fresenius Kabi, a leading global health care company. Together, we intend to transform the standard of care for North American health care providers and patients by providing the highest level of safe and effective integrated infusion care,” Jorgen B. Hansen, Ivenix’s Chief Executive Officer The Ivenix Infusion System includes a large-volume infusion pump with administration sets, infusion management tools, and analytics to inform care and advance efficiency. Ivenix centered the system around the patient and clinician and designed it to reduce infusion-related errors and drive down the total cost of ownership. After receiving U.S. Food and Drug Administration (FDA) clearance, Ivenix successfully launched the infusion system in 2021. “Combining Ivenix’s expertise in pump technology and software with our infrastructure, portfolio, and presence in hospital settings represents an ideal opportunity. We intend to scale the launch of Ivenix’s next-generation infusion system while driving growth opportunities in the United States. With today’s announcement, Fresenius Kabi expects to create a leading, comprehensive infusion therapy offering,” said Michael Sen, President and CEO, Fresenius Kabi. About Ivenix Ivenix, Inc. is a medical technology company with a vision to eliminate infusion-related patient harm. The company was founded to develop innovative solutions that transform infusion delivery. Ivenix designed an infusion system from the ground up to streamline medication delivery and bring infusion technology into the digital age. The Ivenix Infusion System includes a large-volume infusion pump supported by a robust infusion management system designed to set new standards in simplicity, intelligence, and reliability. For more information, visit ivenix.com. The Ivenix Infusion System is cleared by the FDA.

Read More

HEALTH TECHNOLOGY

KLAS and Phreesia Partner to Deliver Patient Insights on Healthcare Technology

KLAS, Phreesia | May 30, 2022

KLAS, a healthcare research and insights firm, and Phreesia, a leader in patient intake, outreach and activation, are pleased to announce the release of a report that aims to shed light on patients’ preferences and expectations for the technology they interact with as a part of their healthcare experience. The report is the result of a survey designed to better understand patient sentiments on a range of topics, including how they like to schedule appointments, their participation in telehealth visits and their communication with their doctor. KLAS and Phreesia partnered together on this report because they share a common mission of improving healthcare and the patient experience, and they recognize that patients’ voices and preferences are not always reflected in healthcare technology. The two organizations leveraged the size and scale of Phreesia’s network—which performed more than 100 million patient check-ins in 2021—to get a firsthand perspective of patients’ priorities. "What do patients want?" asked Adam Gale, CEO of KLAS Research. "This report, based on a survey with nearly 13,000 patients, provides deep insights into how providers and vendors can help meet patient preferences." Phreesia surveyed patients across the U.S. over a two-week period in 2021, as they checked in to a doctor’s appointment using Phreesia’s automated intake platform. The quantitative survey asked 14 questions about patients’ experiences using healthcare technology. Respondents represented a wide range of demographic groups across age, education level, race and gender. The report includes many detailed, data-driven insights and recommendations to providers, including Digital access tools are very important to patients: Online appointment self-scheduling and check-in, price transparency and online bill pay are among the offerings patients desire most. Survey responses indicate that patients aged 18-34 are almost twice as likely to choose organizations that have digital access tools. There are gaps between what patients want and what is offered by vendors and provider organizations—for example, the ability to schedule and reschedule an appointment or request a prescription refill online. Patients are still interested in telehealth: Nearly half of respondents had at least one virtual visit in the past year. Of those who did not, 40% reported they are likely to receive care virtually in the future. Only 33% of respondents interact with a provider portal at least once a month, and 26% don’t use a portal at all, with the youngest patients (18-24 years old) most likely to fall into the latter category. The report recommends providers take a multi-pronged approach and offer technology alternatives for things like virtual care and patient communication to better engage those who rarely or never use a portal, in addition to encouraging increased portal adoption. “As the report describes, patients want to be more actively involved in their healthcare, especially since the start of the pandemic. We believe that patient-centered care is critical to the transformation of our healthcare system. It’s incredibly important to us to be able to use our insights to help providers better engage patients and improve their experience. We’re thrilled to partner with KLAS on this valuable work.” Phreesia CEO Chaim Indig This collaboration is a result of Phreesia and KLAS’ common interest in ensuring patients’ voices are heard and that technology reflects their needs and preferences. As part of the non-financial agreement, KLAS performed its own analysis of Phreesia’s data, created this report and maintains editorial rights. KLAS’ partnership with Phreesia is in no way an endorsement of Phreesia’s performance and has had no impact on Phreesia’s standing in KLAS ratings. About KLAS KLAS has been providing accurate, honest, and impartial insights for the healthcare IT (HIT) industry since 1996. The KLAS mission is to improve the world’s healthcare by amplifying the voice of providers and payers. The scope of our research is constantly expanding to best fit market needs as technology becomes increasingly sophisticated. KLAS finds the hard-to-get HIT data by building strong relationships with our payer and provider friends in the industry. Learn more at klasresearch.com. About Phreesia Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, convenient experience, while enabling our clients to enhance clinical care and drive efficiency.

Read More

FUTURE OF HEALTHCARE

The Department of Health - Abu Dhabi collaborates with a leading healthcare company to boost health technology and clinical research

The Department of Health - Abu Dhabi | June 17, 2022

The Department of Health – Abu Dhabi (DoH), the regulator of healthcare in the emirate, signed a Declaration of Collaboration with Johnson & Johnson Middle East FZ-LLC, to support Abu Dhabi's vision in developing a regional hub for clinical research and data generation. The new strategic collaboration seeks to bring innovative treatments and breakthrough solutions to the UAE and the MENA region as well as exchange knowledge across the healthcare sector. Witnessed by HE Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), the signing ceremony happened during the BIO International Convention 2022 which took place between June 13-16 in San Diego, California, U.S. The Declaration of Collaboration between the parties was signed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH and Jamie Phares, Managing Director of Janssen GCC, one of the pharmaceutical companies of Johnson and Johnson. Headed by HE Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), the Abu Dhabi delegation comprised of government officials is visiting the USA this month to explore prospects of joint collaboration within the framework of healthcare at large and life science in specific. Through these strategic collaborations, DoH and Johnson & Johnson Middle East FZ-LLC will explore key potential areas of interest to develop short and long-term projects in the generation of Data and Real-World Evidence (RWE). Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to establish the strength and sustainability of the healthcare sector as well as provide quality care to patients. "We are pleased with all that we have achieved during the Abu Dhabi Life Science Mission thus far. Our collaborations with leading healthcare companies echo Abu Dhabi's ongoing efforts to position itself as a leading life science destination as well as an incubator for innovation. Through our collaboration with Johnson and Johnson Middle East FZ-LLC, we aim to further improve the resilience and sustainability of the healthcare sector as well as provide quality care to patients in Abu Dhabi and worldwide." Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at the Department of Health – Abu Dhabi (DoH)

Read More

MEDICAL DEVICES

Extremity Medical Files Patent Infringement Lawsuit Against Nextremity Solutions, Zimmer Biomet Holdings and Zimmer, Inc.

Extremity Medical, LLC | April 07, 2022

Extremity Medical, LLC, a global medical device company focused on the development of innovative implants and instruments for upper and lower extremities, announcedthat it filed a lawsuit against Nextremity Solutions, Inc.; Zimmer Biomet Holdings, Inc.; and Zimmer, Inc., alleging infringement of an Extremity Medical patent* for its intraosseous fixation platform arising from the marketing of the InCore® Lapidus System by these companies. The complaint was filed in the U.S. District Court for the District of Delaware. Extremity Medical has amassed an intellectual propertyportfolio that includes 49 patents in the U.S. and several foreign countries. The novel and patented technology of Extremity’s intraosseous fixation platform provides surgeons with a zero-profile solution for fusion and fixation of bones within the upper and lower extremities, with the ability to be implanted through minimal incisions. This technology is currently marketed globally by Extremity under the trade names IO FiX, IO FiX Plus, IO FiX 2.0, IO Freedom, CarpalFiX, ApeX and XMCP. “Extremity Medical has invested a tremendous amount of effort and resources in research and development to create innovative technology to improve the lives of patients and meet surgeons’ needs. Our intellectual property is a critical component in making such advancements possible and we are committed to protecting it,” Matthew Lyons, Extremity Medical Chief Executive Officer, Founder and Chairman of the Board About Extremity Medical, LLC Extremity Medical, was founded in 2008, and is a privately-held medical device company based in Parsippany, NJ. The company is known for creating innovative implants and instruments for upper and lower extremity orthopedic procedures, including fusion and motion preservation. The company is focused on developing solutions for challenging cases that promote better outcomes, especially in patients with poor bone quality.

Read More

Spotlight

This white paper will outline ways a cloud-based patient relationship management solution can be used to increase revenue for healthcare providers, reduce administrative costs, and give physicians and staff more time focusing on patient care.

Resources